About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 710502, 7 pages
http://dx.doi.org/10.1155/2013/710502
Research Article

A Polyethylenimine-Linoleic Acid Conjugate for Antisense Oligonucleotide Delivery

1Institute of Life Sciences, Jilin University, Changchun, Jilin 130023, China
2Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA

Received 4 January 2013; Revised 28 April 2013; Accepted 5 May 2013

Academic Editor: Susana N. Diniz

Copyright © 2013 Jing Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. Braasch and D. R. Corey, “Novel antisense and peptide nucleic acid strategies for controlling gene expression,” Biochemistry, vol. 41, no. 14, pp. 4503–4510, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. K. T. Flaherty, J. P. Stevenson, and P. J. O'Dwyer, “Antisense therapeutics: lessons from early clinical trials,” Current Opinion in Oncology, vol. 13, no. 6, pp. 499–505, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. J. B. Opalinska and A. M. Gewirtz, “Nucleic-acid therapeutics: basic principles and recent applications,” Nature Reviews Drug Discovery, vol. 1, no. 7, pp. 503–514, 2002. View at Scopus
  4. T. Aboul-Fadl, “Antisense oligonucleotides: the state of the art,” Current Medicinal Chemistry, vol. 12, no. 19, pp. 2193–2214, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. B. L. Davidson and P. B. McCray, “Current prospects for RNA interference-based therapies,” Nature Reviews Genetics, vol. 12, no. 5, pp. 329–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. A. Stein and Y. C. Cheng, “Antisense oligonucleotides as therapeutic agents—is the bullet really magical?” Science, vol. 261, no. 5124, pp. 1004–1012, 1993. View at Scopus
  7. S. Mani, C. M. Rudin, K. Kunkel et al., “Phase I clinical and pharmacokinetic study of protein kinase C-α antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer,” Clinical Cancer Research, vol. 8, no. 4, pp. 1042–1048, 2002. View at Scopus
  8. G. Monteleone, M. C. Fantini, S. Onali, et al., “Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease,” Molecular Therapy, vol. 20, no. 4, pp. 870–876, 2012. View at Publisher · View at Google Scholar
  9. C. S. Zent, B. J. Smith, Z. K. Ballas, et al., “Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 53, no. 2, pp. 211–217, 2012.
  10. E. Fattal and G. Barratt, “Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA,” British Journal of Pharmacology, vol. 157, no. 2, pp. 179–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. de Rosa and M. I. La Rotonda, “Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties,” Molecules, vol. 14, no. 8, pp. 2801–2823, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Agrawal, J. Temsamani, W. Galbraith, and J. Tang, “Pharmacokinetics of antisense oligonucleotides,” Clinical Pharmacokinetics, vol. 28, no. 1, pp. 7–16, 1995. View at Scopus
  13. Y. Lee, A. Vassilakos, N. Feng et al., “GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors,” International Journal of Oncology, vol. 28, no. 2, pp. 469–478, 2006. View at Scopus
  14. Y. Ko, S. North, S. R. Berry, et al., “Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 18, p. 98S, 2006.
  15. A. Akinc, M. Thomas, A. M. Klibanov, and R. Langer, “Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis,” Journal of Gene Medicine, vol. 7, no. 5, pp. 657–663, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Boussif, M. A. Zanta, and J. P. Behr, “Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold,” Gene Therapy, vol. 3, no. 12, pp. 1074–1080, 1996. View at Scopus
  17. R. Kircheis, L. Wightman, A. Schreiber et al., “Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application,” Gene Therapy, vol. 8, no. 1, pp. 28–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Boussif, F. Lezoualc'h, M. A. Zanta et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 16, pp. 7297–7301, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Deng, Y. Yue, F. Jin et al., “Revisit the complexation of PEI and DNA—how to make low cytotoxic and highly efficient PEI gene transfection non-viral vectors with a controllable chain length and structure?” Journal of Controlled Release, vol. 140, no. 1, pp. 40–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Tian, W. Xiong, J. Wei et al., “Gene transfection of hyperbranched PEI grafted by hydrophobic amino acid segment PBLG,” Biomaterials, vol. 28, no. 18, pp. 2899–2907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Boeckle, K. von Gersdorff, S. van der Piepen, C. Culmsee, E. Wagner, and M. Ogris, “Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer,” Journal of Gene Medicine, vol. 6, no. 10, pp. 1102–1111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Thomas, Q. Ge, J. J. Lu, J. Chen, and A. M. Klibanov, “Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo,” Pharmaceutical Research, vol. 22, no. 3, pp. 373–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Forrest, J. T. Koerber, and D. W. Pack, “A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery,” Bioconjugate Chemistry, vol. 14, no. 5, pp. 934–940, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. G. P. Tang, Z. Yang, and J. Zhou, “Poly(ethylenimine)-grafted-poly[(aspartic acid)-co-lysine], a potential non-viral vector for DNA delivery,” Journal of Biomaterials Science, Polymer Edition, vol. 17, no. 4, pp. 461–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Gharwan, L. Wightman, R. Kircheis, E. Wagner, and K. Zatloukal, “Nonviral gene transfer into fetal mouse livers (a comparison between the cationic polymer PEI and naked DNA),” Gene Therapy, vol. 10, no. 9, pp. 810–817, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Kim, J. S. Choi, H. S. Jang, H. Suh, and J. Park, “Hydrophobic modification of polyethyleneimine for gene transfectants,” Bulletin of the Korean Chemical Society, vol. 22, no. 10, pp. 1069–1075, 2001. View at Scopus
  27. L. S. Teng, J. Xie, L. R. Teng, and R. J. Lee, “Enhanced siRNA delivery using oleic acid derivative of polyethylenimine,” Anticancer Research, vol. 32, no. 4, pp. 1267–1271, 2012.
  28. Z. Yang, W. Sun, and K. Hu, “Adenosine A1 receptors selectively target protein kinase C isoforms to the caveolin-rich plasma membrane in cardiac myocytes,” Biochimica et Biophysica Acta, vol. 1793, no. 12, pp. 1868–1875, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Yang, W. Sun, and K. Hu, “Molecular mechanism underlying adenosine receptor-mediated mitochondrial targeting of protein kinase C,” Biochimica et Biophysica Acta, vol. 1823, no. 4, pp. 950–958, 2012. View at Publisher · View at Google Scholar
  30. T. I. Kim, J. U. Baek, J. K. Yoon, J. S. Choi, K. Kim, and J. S. Park, “Synthesis and characterization of a novel arginine-grafted dendritic block copolymer for gene delivery and study of its cellular uptake pathway leading to transfection,” Bioconjugate Chemistry, vol. 18, no. 2, pp. 309–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. E. M. van der Aa, U. S. Huth, S. Y. Häfele et al., “Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells,” Pharmaceutical Research, vol. 24, no. 8, pp. 1590–1598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Zhang, J. T. Newsome, R. Mewani, J. Pei, P. C. Gokhale, and U. N. Kasid, “Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs,” Methods in Molecular Biology, vol. 480, pp. 65–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Yu, X. Zhao, J. L. Lee, and R. J. Lee, “Targeted delivery systems for oligonucleotide therapeutics,” AAPS Journal, vol. 11, no. 1, pp. 195–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Li and F. C. Szoka Jr., “Lipid-based nanoparticles for nucleic acid delivery,” Pharmaceutical Research, vol. 24, no. 3, pp. 438–449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. P. P. Karmali and A. Chaudhuri, “Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises,” Medicinal Research Reviews, vol. 27, no. 5, pp. 696–722, 2007. View at Publisher · View at Google Scholar · View at Scopus